Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study

Kayo Kayahashi¹, Yasunari Mizumoto¹*, Ayumi Matsuoka¹, Takeshi Obata¹, Junpei Iwadare¹, Mitsuhiro Nakamura¹, Takiko Daikoku² and Hiroshi Fujiwara¹

Abstract

Background: Aberrant expression of P-cadherin has been reported in various cancers, and has been attracting attention as a target for cancer treatment. Ovarian cancer, the leading cause of death among gynecologic malignancies, is classified into four histological subtypes: serous, mucinous, endometrioid, and clear cell, and each has distinct biological behavior. Although a negative survival impact in serous ovarian cancer patients and some functional role in peritoneal dissemination have been reported, differences of P-cadherin expression in histological subtypes and the proportion and distribution of positive cells remain to be investigated. The aims of this study were to clarify the histological and distributional profiles of P-cadherin expression in ovarian cancer for development of target-therapy in near future.

Methods: A total of 162 primary, 60 metastatic, and 8 recurrent tumors (all cases from 162 ovarian cancer patients) were enrolled in the study. Immunohistochemistry was performed for P-cadherin expression. Associations with clinicopathological characteristics and survival were analyzed.

Results: P-cadherin expression showed a strong correlation with the FIGO stage, histological subtypes, positive peritoneal dissemination (P < 0.01), positive distant metastasis (P < 0.05), and trend toward negative overall survival probability (P = 0.050). P-cadherin was intensely and broadly expressed in mucinous, endometrioid, and serous subtypes (P < 0.01). Disseminated tumors demonstrated similar P-cadherin expression to primary tumors whereas metastatic lymph nodes demonstrated significantly decreased expression (P < 0.01).

Conclusions: Mucinous, endometrioid, and serous ovarian cancer patients accompanied with peritoneal disseminations are the most potent candidates for P-cadherin targeted drug delivery strategies. P-cadherin-targeted therapy may benefit and improve survival of poor-prognosis populations.

Keywords: P-cadherin expression, Ovarian cancer, Antibody-drug conjugate, Target therapy
Background

Epithelial ovarian cancer is associated with the highest mortality among gynecologic cancers [1]. Approximately 60–70% of patients are detected in an advanced stage (stages III and IV) at the time of diagnosis, because ovarian cancer rarely disseminates through the vasculature but has a tendency to metastasize to the peritoneum, unlike many other types of solid tumors [2] [3]. These patients with peritoneal dissemination at diagnosis have a 5-year survival rate of less than 30% and a very high recurrence rate even with a successful response to surgery or chemotherapy [1] [2] [4]. In recent years, successful improvement of survival with newly developed therapeutic agents, such as anti-angiogenic agents and poly ADP ribose polymerase (PARP) inhibitors, has been reported [5] [6] [7]. However, the mortality rate of ovarian cancer patients is still far from satisfactory, and so a new therapeutic strategy is warranted.

P-cadherin, a member of classical cadherin superfamily, is a cell adhesion factor first reported in 1986 as a new subtype of the cadherin found in mouse embryonic development [8]. Besides its regulatory role in implantation, embryo morphogenesis, cellular homeostasis, cell differentiation, cell shape, cell polarity, and growth and migration in fetal development [8] [9] [10], aberrant expression in various cancers has been reported. Since it is only faintly expressed in limited organs of normal adult tissue, it has been attracting attention as a therapeutic target.

Some studies on P-cadherin and ovarian cancer have been reported. Decreased E-cadherin and increased P-cadherin expression, so-called cadherin switching, has been observed when a tumor progresses from stage I to II, indicating its functional role at the stage of cancer spreading from the primary lesion to pelvic cavity [11] [12]. High expression of P-cadherin was reported to have a negative impact on survival in patients with high-grade serous subtypes of ovarian cancer [12]. Moreover, using the mouse ovarian cancer xenograft model, inhibition of P-cadherin by RNAi resulted in decreased peritoneal implantation [3]. These reports suggest the involvement of P-cadherin in ovarian cancer progression and the effectiveness of developing treatment targeting P-cadherin for ovarian cancer; however, the precise profile of P-cadherin expression in terms of histological subtypes, and the proportion and distribution of positive cancer cells in metastatic lesions and association with clinicopathological characteristics, are largely unknown. The aims of this study were to provide the expression profiles of P-cadherin in ovarian cancer, which are mandatory for development of targeted therapy in near future.

Methods

Patients and tissue samples

We recruited 162 patients with epithelial ovarian cancer who underwent primary debulking surgery or exploratory laparotomy between 2008 and 2018 at Kanazawa University Hospital, Japan. Patients from whom tissue from the primary lesion at the time of initial surgery was not obtained were excluded from this study. Of the 162 patients with ovarian cancer, 72 were classified in stage I, 16 in stage II, 64 in stage III, and 10 in stage IV. The median follow-up period after surgery was 47.0 months (range: 0.5–141.7). Formalin-fixed paraffin-embedded blocks of 162 primary lesions, 60 metastatic lesions, and eight recurrent tumors of 162 ovarian cancer patients were retrieved from the Department of Pathology, Kanazawa University Hospital, Japan. The study protocol was approved by the ethical committee of Kanazawa University and preoperative informed consent was obtained from the patients.

Immunohistochemical staining and scoring

Immunohistochemical staining (IHC) was performed on 3-μm, formalin-fixed, paraffin-embedded sections. Each section was deparaffinized in xylene and rehydrated in ethanol, and antigen retrieval was subsequently performed for 15 min. The slides were immersed in 0.3% hydrogen peroxide for 20 min to block endogenous peroxidase activity and then washed in 0.05 M phosphate-buffered saline (PBS, pH 7.4). After blocking, the slides were incubated with mouse monoclonal antibodies against P-cadherin (clone 56; BD Bioscience) at a concentration of 2.5 μg/mL (a dilution of 1:100) overnight at 4 °C. After washing, the sections were incubated for 30 min with biotin-labeled horse anti-mouse IgG at room temperature. Consequently, sections were treated with the avidin-biotin complex (VECTASTAIN ABC kit; Vector Laboratories, Burlingame, USA) at room temperature. Sites of peroxidase activity were visualized with diaminobenzidine (Liquid DAB+ Substrate Chromogen System; Dako, Carpenteria, USA). After being counterstained with hematoxylin, sections were dehydrated and mounted. Expression analysis of proteins in malignant cells was performed by comparing staining intensity and the percentage of immunoreactive cells. Staining intensity was scored (IS: intensity score) on a scale of four grades: 0 (no staining of cancer cells), 1 (weak staining), 2 (moderate staining), and 3 (strong staining) (Fig. 1a), and the positive percentage score (PPS) was determined by the rate of stained cancer cells as follows: 0 (0%), 1 (1 to 10%), 2 (11 to 50%), and 3 (> 50%). The sum of IS and PPS was termed the “P-cadherin score”, and a P-cadherin score of 4 or higher was defined as a “high” score whereas 3 or lower was defined as “low”. The accuracy of antibody testing was confirmed by Western blotting. An extract of chorionic villi was used as a positive control, as previously reported [13].

Statistical analysis

All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria)
More precisely, it is a modified version of R commander designed to add statistical functions frequently used in biostatistics. The association between the immunoreactive markers and clinicopathological features was analyzed using the Chi-squared test. The survival rates were assessed by the Kaplan-Meier method and compared by the log-rank test. To estimate risk factors for recurrence and survival by Cox proportional hazards regression analysis, continuous variables were converted into binary values. Continuous variables were compared using the Kruskal-Wallis test and the Wilcoxon signed-rank test, and are presented as the median and interquartile range. P < 0.05 was considered significant.

Results

P-cadherin expression is strongly correlated with histologic subtype and progressive clinicopathological features of ovarian cancer

We investigated the association between P-cadherin expression and clinicopathological features of ovarian cancer using IHC in 162 patients with ovarian cancer. IHC was performed on 162 primary lesions, 60 metastatic lesions, and 8 recurrent lesions. In the primary lesions, high expression of P-cadherin was observed in 95 of 162 cases (58.6%) (Table 1). P-cadherin was expressed on the cell membrane and in the cytoplasm, but not nucleus, of tumor cells (Fig. 1a). P-cadherin expression was significantly correlated with the International Federation of Gynecology and Obstetrics (FIGO) stage (P = .0024), peritoneal dissemination (P < .001), distant-site metastasis (P = .048), and histologic type (P < .001) (Table 1). As assessed by Kaplan-Meier survival analysis, patients with high expression of P-cadherin, although not significant, showed a trend toward a negative survival probability, as indicated by disease-free survival (DFS) and overall survival (OS) (P = .058, Fig. 2a; P = .050, Fig. 2b). Univariate analysis revealed that CA125, stage, peritoneal dissemination, and histologic type were indicators of DFS and OS. In multivariate analysis, CA125, stage, peritoneal dissemination, and histologic type, but not P-cadherin expression, were found to be independent prognostic factors (Table 3).

Table 1 Immunohistochemistry score of P-cadherin in each histological subtype

A: Intensity score (IS)

| Histologic type | Intensity score (%) |
|-----------------|--------------------|
|                 | 0  | 1  | 2  | 3  |
| Clear cell      | 34 | 18 (52.9) | 13 (38.2) | 3 (8.8) | 0 (0) |
| Endometrioid    | 30 | 1 (3.3) | 8 (26.7) | 16 (53.3) | 5 (16.7) |
| Mucinous        | 23 | 5 (21.7) | 7 (30.4) | 10 (43.5) | 1 (4.4) |
| Serous          | 75 | 7 (9.3) | 14 (18.7) | 44 (58.7) | 10 (13.3) |
| All patients    | 162| 31 (19.1) | 42 (25.9) | 73 (45.1) | 16 (9.9) |

B: Positive percent score (PPS)

| Histologic type | Positive percentage score (%) |
|-----------------|-------------------------------|
|                 | 0  | 1  | 2  | 3  |
| Clear cell      | 34 | 18 (52.9) | 6 (17.6) | 6 (17.6) | 4 (11.8) |
| Endometrioid    | 30 | 1 (3.3) | 7 (23.3) | 2 (6.7) | 20 (66.7) |
| Mucinous        | 23 | 5 (21.7) | 3 (13.0) | 4 (17.4) | 11 (47.8) |
| Serous          | 75 | 7 (9.3) | 6 (8.0) | 9 (12.0) | 53 (70.7) |
| All patients    | 162| 31 (19.1) | 22 (13.5) | 21 (13.0) | 88 (54.3) |

C: P-cadherin score (Sum of IS and PPS)

| Histologic type | Total score (%) |
|-----------------|-----------------|
|                 | Low  | High |
| Clear cell      | 34   | 30 (88.2) | 4 (11.8) |
| Endometrioid    | 30   | 9 (30.0) | 21 (70.0) |
| Mucinous        | 23   | 12 (52.2) | 11 (47.8) |
| Serous          | 75   | 16 (21.3) | 59 (78.7) |
| All patients    | 162  | 67 (41.4) | 95 (58.6) |

Immunohistochemistry score of P-cadherin in each histological subtype. a: intensity score, b: positive percentage score, c: P-cadherin score.
P-cadherin was intensely and broadly expressed in endometrioid and serous subtypes of ovarian cancer

We examined the difference in P-cadherin expression due to differences in histologic subtype. Tissue samples from primary lesions were obtained in 34 cases of clear cell carcinoma, 30 cases of endometrioid carcinoma, 23 cases of mucinous carcinoma, and 75 cases of serous carcinoma. P-cadherin scores for each histological subtype were compared by the Kruskal-Wallis test. A significant difference in the P-cadherin score was confirmed due to the difference in histological subtypes. Especially, endometrioid, serous, and mucinous carcinoma showed significantly high P-cadherin scores whereas the clear cell subtype showed significantly low P-cadherin scores (Fig. 3). Regarding the intensity score (IS), 21/30 (70%) and 54/70 (72%) of cases expressed IS 2 or more in endometrioid and serous subtypes respectively, whereas mucinous carcinoma demonstrated IS 1 or lower in 11/23 (47.9%) (Table 1a). On the other hand, regarding the positive percent score (PPS), 20/30 (66.7%) and 53/73 (70.7%) cases of endometrioid and serous subtypes, demonstrated P-cadherin expression in over 50% of cancer cells, respectively (Table 1b). These results indicate intense and widespread expression of P-cadherin in serous and endometrioid subtypes of ovarian cancer.

Expression level of P-cadherin in primary tumor was preserved in peritoneal dissemination but reduced in metastatic lymph nodes

We investigated the expression of P-cadherin in primary and metastatic tumors. Samples were obtained simultaneously during surgical treatment. In crude analysis, there was no significant difference in P-cadherin scores of primary and metastatic lesions (data not shown). As shown in Table 2, since high expression of P-cadherin in primary lesions was significantly correlated with peritoneal dissemination, but not with lymph node metastasis, we compared P-cadherin scores of primary lesions with disseminated lesion or metastatic lymph nodes, respectively. In the comparison between primary tumors and disseminated lesions, there was no difference in P-cadherin scores (Fig. 4a). On the other hand, P-cadherin expression was reduced in metastatic lymph nodes when compared with primary tumors. (Fig. 4b).

Recurrent lesion demonstrated equivalent P-cadherin expression to primary lesion in small group of samples

To evaluate the change of P-cadherin expression in primary and recurrent lesions, we analyzed samples of primary and recurrent lesions in eight cases. Crude analysis of eight cases demonstrated equivalent P-cadherin scores in primary tumors and recurrent lesions (Fig. 4c). Of the eight cases, two presented with either no or low P-cadherin in primary tumors and recurrent foci. Six cases of endometrioid or serous subtypes presented with similar P-cadherin scores in recurrent foci and primary tumors (Table S1). Five cases with recurrence at the peritoneum demonstrated similar P-cadherin scores with primary tumors. These results suggest that the P-cadherin expression level is predictable from the primary tumor, although this is based on a small sample size, and so necessitates further investigation.

Discussion

This is the first study to demonstrate the expression profile of P-cadherin in ovarian cancer patients from the viewpoint of histology and tumor distribution for target therapy. First, we documented that P-cadherin was strongly correlated with unfavorable prognostic factors, with a trend toward poor survival. Second, we showed that P-cadherin is intensely and broadly expressed in specific tissue subtypes. Third, we showed that the
expression pattern of P-cadherin in the primary lesion was preserved in the disseminated lesions and probably in recurrent lesions, but was reduced in metastatic lymph nodes. Together, these findings will shed light on the future development of drug-delivery strategies targeting P-cadherin in advanced ovarian cancer.

The most important finding of this study was that we clarified the expression profile of P-cadherin in ovarian cancer patients. In endometrioid and serous subtypes, 21/30 (70%) and 59/75 (78.7%) were classified as “High”, with a total immunohistochemistry score of 4 or more, whereas 18/34 (52.9%) of the clear cell subtype did not express P-cadherin at all and 30/34 (88.2%) were classified as “Low” in primary lesions. These results indicate that patients with specific subtypes of ovarian cancer are candidates for P-cadherin-targeted treatment. Furthermore, when P-cadherin expression in metastatic foci was evaluated, interestingly, corresponding disseminated foci showed similar staining to the primary foci, but it was decreased in metastatic lymph nodes (Fig. 4). Decreased E-cadherin and increased P-cadherin, called cadherin switching, has been observed when cancer progresses from FIGO stages I to II, when cancer cells spread from the primary tumor to pelvic cavity [11] {Patel, 2003 #489} [12]. Some of the mechanisms have been reported. Cheung LW et al. reported that promotions of cell migration and invasion by gonadotrophin releasing hormone (GnRH) via activation of p120 catenin signaling are mediated by the P-cadherin/insulin-like growth factor-1 receptor (IGF-1R) complex. Usui et al., using an in vitro and mouse xenograft model of ovarian cancer, demonstrated that inhibition of P-cadherin by RNAi decreased the aggregation and survival of cancer cells floating in ascites and reduced the number of peritoneal implants [3]. Taken together, these reports suggest that P-cadherin contributes to the establishment of peritoneal dissemination in ovarian cancer. Our results further indicate that P-cadherin is broadly and strongly maintained after the completion of dissemination and that P-cadherin-targeting therapy may have effects on a wide range of lesions including not only primary but also disseminated foci. From another perspective, it is suggested that biopsy of the disseminated foci acts as a substitute when biopsy of the primary lesion is difficult or highly invasive. On the contrary, P-cadherin expression was reduced in metastatic lymph nodes compared with that in concomitant primary lesions. The effect of P-cadherin-targeted therapy may not be predictable based on P-cadherin expression of the primary tumors thus, sampling is mandatory when treating patients with lymph node metastases. In fact, P-cadherin expression of dissected recurrent metastatic lymph node metastases demonstrated a similar P-cadherin score to the primary tumor (Table S1), and so the patient may benefit from P-cadherin-targeted therapy. We also examined the P-cadherin expression in recurrent foci in contrast to the primary lesion. Although it is a small-scaled analysis, the P-cadherin expression pattern was maintained in the

Fig. 3 Differences in P-cadherin scores were compared among histologic subtypes. The P-cadherin score was assessed by the sum of the Intensity Score (IS) and Positive Percentage Score (PPS) in primary tumors of 162 patients. *P < 0.01
Another important finding in this study was elucidation of the correlation of prognostic factors with P-cadherin in ovarian cancer patients. P-cadherin expression was significantly correlated with the histological subtype and unfavorable clinicopathologic features of ovarian cancer patients, including a high FIGO stage, positive peritoneal dissemination, and distant site metastases. Although not significant, patients with high P-cadherin expression showed a trend toward shorter DFS and OS on univariate survival analysis (Table 3, Fig. 2). When the survival analysis was limited to P-cadherin high-expressing subtypes, mucinous, endometrioid, and serous subtypes, the Kaplan-Meier survival curve demonstrated significantly decreased survival probability of DFS \( (P = 0.0264) \) and OS \( (P = 0.0227) \) in the P-cadherin High population (Fig. S1). In multivariate analysis, CA125, stage, peritoneal dissemination, and histological type, but not P-cadherin expression, were confirmed as independent prognostic factors in ovarian cancer patients. Together with clinicopathological analysis, P-cadherin may act as a confounder of other prognostic factors. As Van Marck et al. [15] reported, the impact of P-cadherin on survival differs in cancer types. In gastric [16] and oral [17] cancer, it has reported to be a good prognostic factor whereas in breast [18] [19], endometrial [20], gallbladder [21], colon [22], and pancreatic cancer [23], its overexpression indicates a poor prognosis. The fact that P-cad expression strongly correlates with unfavorable prognostic factors in ovarian cancer patients indicates that P-cadherin-targeted treatment benefits such a population, and the development of

### Table 2

Clinicopathological characteristics of the 162 patients in association with P-cadherin expression

| Variable                        | P-cadherin |  | \( P \)-value |
|---------------------------------|------------|---|---------------|
| **Low**                         | **High**   |   |               |
| Age, mean ± SD (years)          | 55.8 ± 11.5| 55.7 ± 12.9 | .428          |
| PS (no.)                        |            |   | .627          |
| 0                               | 52         | 67 |               |
| 1                               | 11         | 20 |               |
| 2 or 3                          | 4          | 8  |               |
| CA125 (no.)                     |            |   | .262          |
| ≤136                            | 37         | 42 |               |
| >136                            | 30         | 51 |               |
| NA                              | 0          | 2  |               |
| Stage a(FIGO2014) (no.)         |            |   | .0024*        |
| Stage I/II                      | 46         | 42 |               |
| Stage III/IV                    | 21         | 53 |               |
| Peritoneal dissemination (no.)  |            |   | 2.7e-5*       |
| Positive                        | 18         | 58 |               |
| Negative                        | 49         | 37 |               |
| Lymph node metastasis b(no.)    |            |   | .823          |
| Positive                        | 9          | 15 |               |
| Negative                        | 58         | 80 |               |
| Distant site metastasis b(no.)  |            |   | .048*         |
| Positive                        | 1          | 9  |               |
| Negative                        | 65         | 86 |               |
| Histologic type c(no.)          |            |   | 1.37e-10*     |
| Clear cell                      | 30         | 4  |               |
| Endometrioid                    | 9          | 21 |               |
| Mucinous                        | 12         | 11 |               |
| Serous                          | 16         | 59 |               |

Clinicopathological characteristics of the 162 patients in association with P-cadherin expression

* \( P < 0.05 \); ** Cutoff value as the median value. **Pathological diagnosis. NA not available

---

**Fig. 4** P-cadherin scores in primary, metastatic, and recurrent lesions were analyzed. 
- **A**: P-cadherin score of primary tumor and peritoneal dissemination were compared \( (n = 49, P = .89) \).
- **B**: P-cadherin score of primary tumor and metastatic lymph nodes were compared \( (n = 14, *P = .0079) \).
- **C**: P-cadherin score of primary and recurrent tumors were compared \( (n = 8, P = .202) \). * \( P < 0.01 \), NS: not significant
effective treatments may contribute to the improvement of survival.

In recent years, antibody drug therapy is being intensively researched and developed in the field of cancer treatment. Antibody therapy is largely classified into two categories: those that act directly on functional molecules, and those that are used as drug carriers. Numerous monoclonal antibody drugs, which act on functional molecules, have been developed and have proven survival benefits. Although still in the experimental stage, the effectiveness of cell adhesion inhibition by an antibody targeting the X-dimer of P-cadherin has been reported [24]. Further advances in antibody technology have led to the rapid development of an antibody-drug conjugate (ADC) and radioimmunotherapy (RIT) that use antibodies specifically binding to cancer antigens as carriers. The first ADC approved by U.S. Food and Drug Administration (FDA) was Gemtuzumab ozogamicin for acute myelogenous leukemia (AML) in 2001 [25]. Since then, several ADCs, such as Brentuximab vedotin for relapsed Hodgkin’s lymphoma (HL), systemic anaplastic large cell lymphoma (sALCL), Trastuzumab emtansine for HER2-positive metastatic breast cancer, and Inotuzumab ozogamicin for relapsed CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL), have been applied in clinical practice. As for RIT, Ibritumomab tiuxetan and Iodine tositumomab, both of which use anti-CD20 to conjugate Yttrium-90 or Iodine-131, respectively, have been used to treat non-Hodgkin’s lymphoma patients [26]. Because P-cadherin shows faint expression in normal adult tissues in restricted organs such as hair follicles and the breast [27], and aberrant expression in numerous cancers [18][19][20][21][22][23], drug-delivery systems targeting P-cadherin as a tumor-associated antigen are attractive treatment strategies. In this study, advanced ovarian cancer, especially endometrioid and serous subtypes, demonstrated intense and broad expression of P-cadherin not only in primary

### Table 3

| Factors                        | n   | Disease-free survival | Overall survival |
|--------------------------------|-----|-----------------------|------------------|
|                                |     | Univariate            | Multivariate     | Univariate | Multivariate |
|                                |     | P-value   HR 95%CI P-value | P-value   HR 95%CI P-value |
| Age * (years)                  |     | .187      | .176             |
| ≤ 55                           | 79  | .176      | .176             |
| > 55                           | 83  | .176      | .176             |
| CA125a                         |     | 6.3e-4*   | 2.29 1.08–4.84 .030* | .0017*  2.31 1.10–4.84 .027* |
| ≤136                           | 79  | .030*     | 2.31 1.10–4.84 .027* |
| > 136                          | 81  | .030*     | 2.31 1.10–4.84 .027* |
| Stageb (FIGO2014)              |     | 1.0e-7*   | 3.40 1.32–8.80 .011* | 4.9e-7*  4.03 1.53–10.6 .0048* |
| Stage I/II                     | 88  | .011*     | 4.03 1.53–10.6 .0048* |
| Stage III/IV                   | 74  | .011*     | 4.03 1.53–10.6 .0048* |
| Peritoneal dissemination       |     | 5.0e-8*   | 4.06 1.42–11.6 .0090* | 2.5e-6*  2.94 1.03–8.38 .044* |
| Positive                       | 76  | .0090*    | 2.94 1.03–8.38 .044* |
| Negative                       | 86  | .0090*    | 2.94 1.03–8.38 .044* |
| Lymph node metastasis          |     | .091      | .109             |
| Positive                       | 24  | .109      |                  |
| Negative                       | 138 | .109      |                  |
| Distant site metastasis        |     | .062      | .095             |
| Positive                       | 10  | .095      |                  |
| Negative                       | 152 | .095      |                  |
| Histologic typeb               |     | .014*     | 0.42 0.20–0.92 .029* | 0.42 0.19–0.93 .032* |
| Serous                         | 75  | .029*     | 0.42 0.19–0.93 .032* |
| Others                         | 87  | .032*     | 0.42 0.19–0.93 .032* |
| P-cadherin                     |     | .058      | 1.18 0.56–2.49 .669 | .050   1.19 0.55–2.58 .653 |
| High                           | 95  | .669      |                  |
| Low                            | 67  | .653      |                  |

Univariate and multivariate analyses of predictive factors for survival in ovarian cancer patients

*P < 0.05. *Cutoff value as the median value. *Pathological diagnosis. CI confidence interval; HR hazard ratio.
foci but also in disseminated lesions. Because the dissemination is the main cause of treatment failure and a poor prognosis in ovarian cancer patients, the development of ADC or RIT targeting P-cadherin may be optimal treatment to improve the prognosis of ovarian cancer patients. Although molecular targeting therapy or ADC targeting P-cadherin has yet not been developed, radionuclide bound to P-cadherin antibody has been developed. In the United States, phase 1 clinical trials have been conducted, in which Yttrium-90 bound to anti-P-cadherin antibody (FF21101) was administered to patients with solid tumors [28]. Advanced ovarian cancer, especially the endometrioid or serous subtype, may be a good candidate for such treatment.

A limitation of this study is that we could not obtain and analyze P-cadherin expression in distant metastatic lesions in the lung or liver. The small sample number of recurrent lesions is also a limitation.

Conclusion
In this study, we revealed that P-cadherin was intensely and broadly expressed in ovarian cancer, especially in endometrioid and serous subtypes, and demonstrated preserved expression in disseminated lesions similar to that of primary foci, but not in metastatic lymph nodes. We also demonstrated that P-cadherin expression indicates a poor prognostic tendency in a confounding manner with other unfavorable prognostic factors. We believe that this study provides useful information and will help promote research and development of antibody treatment with P-cadherin as a carrier in ovarian cancer patients.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12885-020-07737-w.

Acknowledgements
Not applicable.

Authors’ contributions
KR: analysis and interpretation of data, writing-original draft; YM: design of the work, substantively revised the draft; AKI: analysis of data; TO: acquisition of data; JI: acquisition and interpretation of data; MN: acquisition of data; TD: analysis and interpretation of data; HF: conception of the work, interpretation of data. All authors have read and approved the manuscript.

Funding
The authors have received no funding for this study.

Availability of data and materials
All datasets used or analyzed for this study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate
The study protocol was approved by the ethical committee of Kanazawa University (2019–314(3327)). All study methods were conducted in accordance with the Declaration of Helsinki. Preoperative written informed consent was obtained from the patients prior to the collection of clinical data from their medical records.

Consent for publication
Not applicable.

Competing interests
The authors declare that there are no conflicts of interest relevant to the content of this study.

Author details
1Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kanazawa University, 13-1, Takaramachi, Kanazawa, Ishikawa 920-8641, Japan. 2Institute for Experimental Animals, Advanced Science Research Center, Kanazawa University, 13-1, Takaramachi, Kanazawa, Ishikawa 920-8641, Japan.

Received: 13 September 2020 Accepted: 15 December 2020

References
1. Segel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7–34.
2. Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer. 2005;5(5):355–66.
3. Usui A, Ko SY, Barengo N, Naora H. P-cadherin promotes ovarian cancer dissemination through tumor cell aggregation and tumor-peritoneum interactions. Mol Cancer Res. 2014;12(4):504–13.
4. Sodek KL, Murphy KJ, Brown TJ, Ringsette MJ. Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev. 2012; 31(1–2):397–414.
5. Rossi L, Venrico M, Zaccarelli E, Papa A, Colonna M, Strudel M, Vici P, Bianco V, Tomao F. Bevacizumab in ovarian cancer: a critical review of phase III studies. Oncotarget. 2017;8:12389–405.
6. Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, Fujwara K, Vergote I, Colombo N, Maenpaa J, et al. Olaparib plus Bevacizumab as first-line maintenance in ovarian Cancer. N Engl J Med. 2019;381(25):2416–28.
7. Hinchcliffe E, Hong D, Le H, Chisholm G, Iyer R, Naing A, Hwu P, Jazaeri A. Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. Gynecol Oncol. 2018;151(3):407–13.
8. Nose A, Takeichi M. A novel cadherin cell adhesion molecule: its expression patterns associated with implantation and organogenesis of mouse embryos. J Cell Biol. 1986;103:2649–58.
9. Cavallaro U, Dejana E. Adhesion molecule signalling: not always a sticky business. Nat Rev Mol Cell Biol. 2011;12(3):189–97.
10. Raymond K, Deugnier MA, Faraldo MM, Gulikova MA. Adhesion within the stem cell niches. Curr Opin Cell Biol. 2009;21(5):623–9.
11. Patel IS, Madan P, Getsios S, Bertrand MA, MacCalman CD. Cadherin switching in ovarian cancer progression. Int J Cancer. 2003;106(2):172–7.
12. Quattrocchi L, Green AR, Martin S, Durrant L, Deen S. The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression. Virchows Arch. 2011;459(1):21–9.
13. Sahin H, Alpak YK, Berber U, Gun I, Demirel D, Ergur AR. Expression of P-cadherin (cadherin-3) and E-selectin in the villous trophoblast of first trimester human placenta. J Turk Ger Gynecol Assoc. 2014;15(1):13–7.
14. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.
15. Van Mack V, Stove C, Jacobs K, Van den Eynden G, Bracke M. P-cadherin in adhesion and invasion: opposite roles in colon and bladder carcinoma. Int J Cancer. 2011;128(5):1031–44.
16. Kim MA, Jung EJ, Lee HS, Lee HE, Yang HK, Oh DY, Bang YJ, Kim WH. P-cadherin expression in gastric carcinoma: its regulation mechanism and prognostic significance. Hum Pathol. 2010;41(6):877–85.
17. Munoz-Guerra MF, Marazuela EG, Fernandez-Contreras ME, Gamallo C. P-cadherin expression reduced in squamous cell carcinoma of the oral cavity: an indication of poor prognosis. Cancer. 2005;103(1):560–9.
18. Paredes J, Alberga A, Oliveira JT, Jeronimo C, Milanesi F, Schmitt FC. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypermethylation. Clin Cancer Res. 2005;11(16):5869–77.
19. Peralta Soler A, Knudsen KA, Salazar H, Han AC, Keshgheian AA. P-cadherin expression in breast carcinoma indicates poor survival. Cancer. 1999;86(7):1263–72.
20. Steffansson IM, Salvesen HB, Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol. 2004;22(7):1242–52.
21. Yi S, Yang ZL, Miao X, Zou Q, Li J, Liang L, Zeng G, Chen S. N-cadherin and P-cadherin are biomarkers for invasion, metastasis, and poor prognosis of gallbladder carcinomas. Pathol Res Pract. 2014;210(6):363–8.
22. Sun L, Hu H, Peng L, Zhou Z, Zhao X, Pan J, Sun L, Yang Z, Ran Y. P-cadherin promotes liver metastasis and is associated with poor prognosis in colon cancer. Am J Pathol. 2011;179(1):380–90.
23. Sakamoto K, Imai K, Higashi T, Taki K, Nakagawa S, Okabe H, Nitta H, Hayashi H, Chikamato A, Ishiko T, et al. Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer. Cancer Sci. 2015;106(9):1153–62.
24. Kudo S, Caeveiro JM, Nagatoshi S, Miyafuji T, Matsuura T, Sudo Y, Tsumoto K. Disruption of cell adhesion by an antibody targeting the cell-adhesive intermediate (X-dimer) of human P-cadherin. Sci Rep. 2017;7:39518.
25. Sievers EL, Larson RA, Stadtmueller EA, Estey E, Löwenberg B, Dombret H, Karanes C, Theobald JM, Sherman ML, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244–54.
26. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov. 2004;3(6):498–99.
27. Imai K, Hirata R, Li X, Arai A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, et al. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res. 2008;14(20):6487–95.
28. A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer (accessed 12 May 2020) [https://clinicaltrials.gov/ct2/show/NCT02454010].

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions